Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis

We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2001, Vol.30 (6), p.356-359
Main Authors: MIKULS, Ted R, KAHN, Daniel, UTRIE, Paul C, MILLER, Sara J, KOEHNKE, Raechelle, GOECKELER, William, SAAG, Kenneth G
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Biological and medical sciences
Diseases of the osteoarticular system. Orthopedic treatment
Drug Resistance
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Pain Measurement
Pilot Projects
Radioisotopes
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Reference Values
Samarium - administration & dosage
Samarium Rheumatoid Arthritis Radioisotope Treatment
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2–4 weeks. Sm-153, at doses of 0.5 and 1.0 mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.
ISSN:0300-9742
1502-7732
DOI:10.1080/030097401317148561